Victor Forge
Colon cancer patients commonly experience muscle loss, which is associated with poorer survival rates. This muscle loss can be caused by the cancer treatment itself, with chemotherapy and radiotherapy leading to substantial weight and muscle loss. Cancer cachexia, defined by an ongoing loss of skeletal muscle mass, is also a common phenomenon in many cancer types, including colorectal cancer. Other factors that contribute to muscle loss in colon cancer patients include tumour stage, type of surgical approach, and lifestyle factors such as smoking.
| Characteristics | Values |
|---|---|
| Muscle loss in colon cancer patients | Colon cancer patients commonly suffer declines in muscle mass and aerobic function |
| Causes of muscle loss | Reduced food intake, low physical activity, abnormal metabolism, and side effects of cancer treatment |
| Cancer cachexia | An ongoing loss of skeletal muscle mass |
| Factors affecting muscle loss | Type of surgical approach, tumor stage, smoking, and treatment intensity |
| Muscle loss and survival | Muscle loss is associated with poor survival in patients with metastatic colorectal cancer |
Explore related products
$13.99
What You'll Learn
- Colon cancer patients often experience muscle mass and function loss
- Cancer cachexia is defined by an ongoing loss of skeletal muscle mass
- Low muscle mass is present in around 40% of metastatic colorectal cancer patients
- Muscle loss during chemotherapy is linked to poor survival rates in metastatic colorectal cancer patients
- Colon cancer patients with muscle weakness: a rare case of polymyositis
Colon cancer patients often experience muscle mass and function loss
There are several factors that contribute to cancer-related muscle wasting during the first-line systemic treatment of metastatic colorectal cancer. These factors include demographic, lifestyle (such as smoking), tumour-related, and treatment-related factors. For example, a study found that patients with male sex and increased systemic inflammation markers lost more muscle mass in the last 24 months of life compared to patients without these factors.
Additionally, cancer treatments themselves often elicit losses of weight and muscle mass. A study found that muscle loss of 9% or more during chemotherapy was independently associated with poorer survival in patients with metastatic colorectal cancer. Furthermore, a study on colon cancer patients without distant metastasis found that post-resection lean mass was reduced in patients, indicating a decline in muscle mass and aerobic function.
The loss of muscle mass in colon cancer patients can be attributed to various causes, including reduced food intake, low physical activity, abnormal metabolism, and tumour activity. Reversing muscle loss in cancer patients can be challenging due to these factors, particularly abnormal metabolism caused by tumour activity, which is referred to as cachexia.
Fibromyalgia: Muscle Stiffness and Its Connection
You may want to see also
Explore related products
Cancer cachexia is defined by an ongoing loss of skeletal muscle mass
Colon cancer patients commonly suffer from declines in muscle mass and aerobic function. A study found that muscle loss of 9% or more during chemotherapy was independently associated with poorer survival.
Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass, with or without the loss of fat mass, resulting in functional impairment and reduced quality of life. It affects approximately 70% of cancer patients and is responsible for up to 22% of cancer deaths. It is caused by the upregulation of systemic inflammation and catabolic stimuli, leading to inhibition of protein synthesis and enhancement of muscle catabolism.
The catabolic pathway in skeletal muscle induces muscle loss because of the loss of proteins, organelles, and cytoplasm, which causes cell shrinkage and muscle atrophy. During cancer cachexia, the skeletal muscle undergoes a reduction in protein synthesis and an increase in protein degradation/proteolysis. These changes are associated with organelle dysfunction marked by the upregulation of inflammatory mediator genes, abnormal expression of angiotensin II (AngII), IGF1, and various receptors, proteins, and kinases.
A variety of systemic antineoplastic agents generate muscle loss directly by expressing direct catabolic actions on muscle cells, as well as secondarily via their systemic (gastrointestinal) side effects that impair food intake during treatment. Muscle wasting is a potential adverse effect that should be considered in the use of current cancer therapies and the development of new ones.
Farxiga and Muscle Pain: What's the Link?
You may want to see also
Explore related products
Low muscle mass is present in around 40% of metastatic colorectal cancer patients
Colon cancer patients commonly experience declines in muscle mass and aerobic function. A study found that low muscle mass is present in around 40% of metastatic colorectal cancer patients. This muscle loss is associated with poor outcomes and lower survival rates.
Several factors contribute to cancer-related muscle wasting in metastatic colorectal cancer patients. These factors include demographic characteristics, lifestyle choices (such as smoking), tumour-related aspects, and treatment-related factors. For instance, skeletal muscle loss is a common phenomenon in many cancer types, and its depletion is associated with poor clinical outcomes such as reduced responsiveness and tolerability to cancer treatment, quality of life, and survival.
Additionally, studies have found that muscle loss is more prevalent during periods of progressive disease and at the end of life. Furthermore, patients with male sex and increased systemic inflammation markers lost more muscle mass in the last 24 months of life compared to those with female sex and lower inflammation markers.
The type of surgical approach and tumour stage also play a role in muscle mass loss. A study reported that loss of skeletal muscle mass was significantly associated with open surgery compared to laparoscopic surgery and higher in stage III–IV tumours compared to stage I–II.
Interventions such as increasing physical activity during treatment and nutritional counselling have been suggested to potentially improve muscle strength and mass in cancer patients. However, further studies are needed to investigate the causes of muscle loss and the effectiveness of interventions.
Muscle Inflammation in Dogs: Shaking and Treatment
You may want to see also
Explore related products
Muscle loss during chemotherapy is linked to poor survival rates in metastatic colorectal cancer patients
Muscle loss during chemotherapy is a common occurrence in patients with metastatic colorectal cancer (mCRC). Several studies have found that this muscle loss is associated with poor survival rates in these patients.
Low muscle mass is present in approximately 40% of patients with mCRC and is linked to a poorer outcome. During palliative chemotherapy, the muscle area of patients with mCRC decreased significantly by 6.1% in 3 months. Patients with muscle loss of 9% or more during treatment had significantly lower survival rates than those with less than 9% muscle loss.
The loss of muscle mass during chemotherapy is a predictor of poor survival in mCRC patients, independent of other factors such as sex, age, and baseline lactate dehydrogenase concentration. This suggests that muscle loss itself is a significant contributor to poorer outcomes in these patients.
There are several factors that contribute to cancer-related muscle wasting in mCRC patients. These include demographic, lifestyle, tumor-related, and treatment-related factors. Smoking, for example, has been identified as a potentially modifiable factor associated with muscle loss. Abnormal metabolism, reduced food intake, low physical activity, and tumor activity are also contributors to low muscle mass.
Interventions such as increasing physical activity during treatment and nutritional counseling have been suggested as possible strategies to attenuate muscle loss and improve clinical outcomes. Nutritional interventions and exercise training may help preserve muscle mass and potentially improve survival rates in mCRC patients undergoing chemotherapy.
Lupus and Muscle Tightness: What's the Connection?
You may want to see also
Explore related products
Colon cancer patients with muscle weakness: a rare case of polymyositis
Colon cancer patients often experience muscle loss and aerobic function decline. This is due to the downregulation of pyruvate dehydrogenase (PDH) activity, which is essential for energy production in skeletal muscle. In addition, the upregulation of the inflammatory cytokine nuclear factor kappa-B (NFκB) contributes to muscle loss in cancer patients.
While colorectal cancer rarely presents with muscle weakness, it is important to consider the possibility of an underlying malignancy when patients exhibit symptoms suggestive of polymyositis. Polymyositis is a rare disease characterized by proximal muscle weakness and is often associated with an underlying cancer diagnosis. This is known as a paraneoplastic syndrome, where symptoms are a consequence of the presence of cancer but are not caused by local tumour effects.
In one case, an 82-year-old man presented with bilateral leg weakness and progressive muscle weakness affecting all four limbs. Clinical examination revealed symmetrical muscle weakness, and an MRI indicated polymyositis. Despite a stable weight and no bowel symptoms, CT images revealed colon thickening and metastases in the liver. This case highlights the importance of considering an underlying malignancy in polymyositis diagnoses, especially in the elderly.
Another case study describes a 72-year-old woman with metastatic colorectal cancer who developed acute-onset muscle weakness after chemotherapy. This could be attributed to paraneoplastic syndrome or immune modulation by chemotherapy. Despite rapid normalization of muscle enzymes with high-dose methylprednisolone and intravenous immunoglobulins, the patient's general status deteriorated, and she passed away. This case underscores the challenge of managing severe polymyositis in cancer patients and the potential drug-induced toxicity of treatments.
In summary, colon cancer patients frequently experience muscle loss due to dysregulation of energy production pathways and increased inflammation. Although rare, polymyositis can be a presenting symptom of colorectal cancer, emphasizing the need for oncology referral and consideration of palliative care. Early recognition of muscle weakness as a paraneoplastic syndrome or treatment-induced toxicity is crucial for patient outcomes.
Codeine's Muscle Cramp Conundrum: What's the Link?
You may want to see also
Frequently asked questions
Colon cancer patients commonly suffer declines in muscle mass and aerobic function. This is often due to a combination of reduced food intake, low physical activity, and abnormal metabolism.
Muscle loss is more likely to occur during periods of systemic treatment and may be influenced by the intensity of treatment regimens.
Muscle loss is associated with poor clinical outcomes such as reduced responsiveness and tolerability to cancer treatment, quality of life, and survival.
